{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:40:47Z","timestamp":1759405247625,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.vaccine.2022.08.026","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T02:22:33Z","timestamp":1661134953000},"page":"6722-6729","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety of the Fiocruz ChAdOx COVID-19 vaccine used in a mass vaccination campaign in Botucatu, Brazil"],"prefix":"10.1016","volume":"40","author":[{"given":"Sue Ann Costa","family":"Clemens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Magno Castelo Branco","family":"Fortaleza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeleine","family":"Crowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen Ingrid","family":"Tasca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rejane Maria Tommasini","family":"Grotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo Roberto","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 Gasparini","family":"Spadaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasqual","family":"Barretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Verstraeten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.08.026_b0005","unstructured":"World Health Organization. WHO Coronavirus (COVID-19) Dashboard. <https:\/\/covid19.who.int\/> [accessed: 19 January 2022]."},{"key":"10.1016\/j.vaccine.2022.08.026_b0010","doi-asserted-by":"crossref","first-page":"e0245011","DOI":"10.1371\/journal.pone.0245011","article-title":"The short-term impacts of coronavirus quarantine in S\u00e3o Paulo: the health-economy trade-offs","volume":"16","author":"Gori Maia","year":"2021","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2022.08.026_b0015","doi-asserted-by":"crossref","unstructured":"Ganem F, Mendes F, de Oliveira S. The impact of early social distancing at COVID-19 Outbreak in the largest Metropolitan Area of Brazil. medRxiv 2020.04.06.20055103.","DOI":"10.1101\/2020.04.06.20055103"},{"key":"10.1016\/j.vaccine.2022.08.026_b0020","doi-asserted-by":"crossref","unstructured":"Fortaleza C, Vilches T, de Almeida G. Impact of nonpharmaceutical governmental strategies for prevention and control of COVID-19 in S\u00e3o Paulo State, Brazil. medRxiv 2020.08.23.20180273.","DOI":"10.1101\/2020.08.23.20180273"},{"key":"10.1016\/j.vaccine.2022.08.026_b0025","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13362-020-00098-w","article-title":"Flattening the curves: on-off lock-down strategies for COVID-19 with an application to Brazil","volume":"11","author":"Tarrataca","year":"2021","journal-title":"J Math Ind"},{"issue":"37","key":"10.1016\/j.vaccine.2022.08.026_b0030","doi-asserted-by":"crossref","first-page":"e00344620","DOI":"10.1590\/0102-311x00344620","article-title":"Challenges for implementation of the COVID-19 vaccination campaign in Brazil","volume":"11","author":"Domingues","year":"2021","journal-title":"Cad Saude Publica"},{"key":"10.1016\/j.vaccine.2022.08.026_b0035","unstructured":"Palacios R, Batista A, Albuquerque C. Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study. SSRN 3822780:"},{"key":"10.1016\/j.vaccine.2022.08.026_b0040","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.08.026_b0045","unstructured":"Sao P\u00e3olo Governo Do Estado. Seade Popula\u00e7\u00e3o. <https:\/\/populacao.seade.gov.br> [accessed: June 3, 2022]."},{"key":"10.1016\/j.vaccine.2022.08.026_b0050","unstructured":"de Paz C, Muller M, Munoz Boudet A, Gaddi I. Gender dimensions of the COVID-19 pandemic. <https:\/\/openknowledge.worldbank.org\/bitstream\/handle\/10986\/33622\/Gender-Dimensions-of-the-COVID-19-Pandemic.pdf%20?sequence=1> [accessed: June 3, 2022]."},{"key":"10.1016\/j.vaccine.2022.08.026_b0055","unstructured":"European Medicines Agency. COVID-19 Vaccine AstraZeneca. <https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vaxzevria-previously-covid-19-vaccine-astrazeneca> [accessed: 19 January 2022]."},{"key":"10.1016\/j.vaccine.2022.08.026_b0060","first-page":"997","article-title":"Bell's palsy: diagnosis and management","volume":"76","author":"Tiemstra","year":"2007","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.vaccine.2022.08.026_b0065","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting","volume":"385","author":"Barda","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.08.026_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(21)00467-9","article-title":"The association between COVID-19 vaccination and Bell's palsy","volume":"22","author":"Cirillo","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.08.026_b0075","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1473-3099(21)00451-5","article-title":"Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study","volume":"22","author":"Wan","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.08.026_b0080","article-title":"Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection","volume":"27","author":"Patone","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2022.08.026_b0085","unstructured":"Medicines and Healthcare products Regulatory Agency. Coronavirus Vaccine \u2013 summary of Yellow Card Reporting Data included: 9\/12\/2020 to 5\/01\/2022. <https:\/\/coronavirus-yellowcard.mhra.gov.uk\/datasummary>."},{"key":"10.1016\/j.vaccine.2022.08.026_b0090","article-title":"mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis","author":"Di Filippo","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.vaccine.2022.08.026_b0095","doi-asserted-by":"crossref","first-page":"102915","DOI":"10.1016\/j.msard.2021.102915","article-title":"COVID-19 and the risk of relapse in multiple sclerosis patients: a fight with no bystander effect?","volume":"51","author":"Etemadifar","year":"2021","journal-title":"Multiple Sclerosis Related Disorder"},{"key":"10.1016\/j.vaccine.2022.08.026_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(18)30443-5","article-title":"Global, regional, and national burden of multiple sclerosis 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Wallin","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.vaccine.2022.08.026_b0105","first-page":"199","article-title":"Multiple sclerosis relapses: epidemiology, outcomes and management","volume":"44","author":"Kalincik","year":"2015","journal-title":"System Rev Neurobiol"},{"key":"10.1016\/j.vaccine.2022.08.026_b0110","unstructured":"European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC) Draft agenda for the meeting on 10-13 January 2022. <https:\/\/www.ema.europa.eu\/en\/documents\/agenda\/agenda-prac-draft-agenda-meeting-10-13-january-2022_en.pdf>."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22010106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22010106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:19:22Z","timestamp":1759403962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22010106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":22,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0264410X22010106"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.08.026","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of the Fiocruz ChAdOx COVID-19 vaccine used in a mass vaccination campaign in Botucatu, Brazil","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.08.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}